$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,300 Today

7/4/24 12:00:24 PM ET

Medical Specialities

Health Care

Get the next $NTRA alert in real time by email

Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 19.94% on an annualized basis producing an average annual return of 33.11%. Currently, Natera has a market capitalization of $13.71 billion.

Buying $1000 In NTRA: If an investor had bought $1000 of NTRA stock 5 years ago, it would be worth $4,293.85 today based on a price of $111.64 for NTRA at the time of writing.

Natera's Performance Over Last 5 Years

comp_fig

Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Get the next $NTRA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NTRA

Date	Price Target	Rating	Analyst
6/3/2024	$142.00	Buy	Jefferies
4/8/2024	$117.00	Buy	Craig Hallum
2/20/2024	$68.00 → $85.00	Strong Buy → Outperform	Raymond James
12/29/2023	$75.00 → $85.00	Buy	BTIG Research
12/14/2023	$70.00	Buy	Guggenheim
12/13/2023	$70.00	Outperform	Wolfe Research
11/13/2023	$68.00	Outperform → Strong Buy	Raymond James
9/28/2023	$48.00	Mkt Perform	Bernstein

More analyst ratings

$NTRA
Press Releases

Fastest customizable press release news feed in the world

Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
Underscores the Company's commitment to generating robust scientific evidence on its leading MRD technology Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it has surpassed a key milestone with over 100 peer-reviewed publications on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera. Multiple validation studies on Signatera have been published in top-tier journals like Nature, Nature Medicine, Nature Cancer, Journal of Clinical Oncology, Annals of Oncology, and JAMA Oncology. These include some of the largest and most comprehensive prospective studies of MRD testing to date. In clinical studies, S
11/21/24 5:31:00 PM ET
$NTRA
Medical Specialities
Health Care
Natera Reports Third Quarter 2024 Financial Results
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $439.8 million in the third quarter of 2024, compared to $268.3 million in the third quarter of 2023, a record increase of 63.9%. Product revenues grew 64.4% over the same period. Generated a gross margin of 61.8% in the third quarter of 2024, compared to a gross margin of 45.1% in the third quarter of 2023. Processed approximately 775,800 tests in the third quarter of 2024, compared to approximately 626,000 tests in the third quarter of 2023, an
11/12/24 4:05:00 PM ET
$NTRA
Medical Specialities
Health Care
Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
First-of-its-kind study of >1K patients evaluating the impact of adjuvant treatment escalation in patients tested with Signatera™; results to be presented at ASCO GI in Jan. 2025 Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced the completion of a study using Signatera from the CALGB (Alliance)/SWOG 80702 randomized, phase III clinical trial. CALGB (Alliance)/SWOG 80702 evaluated the benefit of adding celecoxib to FOLFOX in postoperative treatment of stage III colorectal cancer (CRC) in a biomarker unselected population. This pre-specified analysis includes 1,011 CRC patients with available post-surgical plasma samples and investigates Si
11/12/24 7:00:00 AM ET
$NTRA
Medical Specialities
Health Care

(NTRA) - Analyzing Natera's Short Interest
Natera's (NYSE:NTRA) short percent of float has risen 15.19% since its last report. The company recently reported that it has 6.38 million shares sold short, which is 5.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.14 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is imp
7/23/24 2:00:25 PM ET
$NTRA
Medical Specialities
Health Care
Here's How Much You Would Have Made Owning Natera Stock In The Last 5 Years
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 18.07% on an annualized basis producing an average annual return of 31.07%. Currently, Natera has a market capitalization of $12.47 billion. Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $386.36 today based on a price of $101.57 for NTRA at the time of writing. Natera's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by
7/18/24 5:00:15 PM ET
$NTRA
Medical Specialities
Health Care
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,300 Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 19.94% on an annualized basis producing an average annual return of 33.11%. Currently, Natera has a market capitalization of $13.71 billion. Buying $1000 In NTRA: If an investor had bought $1000 of NTRA stock 5 years ago, it would be worth $4,293.85 today based on a price of $111.64 for NTRA at the time of writing. Natera's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewe
7/4/24 12:00:24 PM ET
$NTRA
Medical Specialities
Health Care

$NTRA
Leadership Updates

Live Leadership Updates

Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer
Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee
6/5/23 11:06:00 AM ET
$NTRA
Medical Specialities
Health Care
Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors
Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations
2/23/23 8:05:00 AM ET
$NTRA
Medical Specialities
Health Care
Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology
AUSTIN, Texas, May 24, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera. "As a highly reg
5/24/22 8:03:00 AM ET
$NTRA
Medical Specialities
Health Care

$NTRA
Financials

Live finance-specific insights

Natera Reports Third Quarter 2024 Financial Results
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $439.8 million in the third quarter of 2024, compared to $268.3 million in the third quarter of 2023, a record increase of 63.9%. Product revenues grew 64.4% over the same period. Generated a gross margin of 61.8% in the third quarter of 2024, compared to a gross margin of 45.1% in the third quarter of 2023. Processed approximately 775,800 tests in the third quarter of 2024, compared to approximately 626,000 tests in the third quarter of 2023, an
11/12/24 4:05:00 PM ET
$NTRA
Medical Specialities
Health Care
Natera to Report its Third Quarter 2024 Results on November 12, 2024
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its third quarter ended Sept. 30, 2024, after the market closes on Nov. 12, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera's Third Quarter 2024 Financial Results Date: Tuesday, Nov. 12, 2024 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID: 7684785 Webc
11/1/24 9:00:00 AM ET
$NTRA
Medical Specialities
Health Care
Natera Reports Second Quarter 2024 Financial Results
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $413.4 million in the second quarter of 2024, compared to $261.4 million in the second quarter of 2023, an increase of 58.1%. Product revenues grew 59.3% over the same period. Generated a gross margin of 58.8% in the second quarter of 2024, compared to a gross margin of 45.2% in the second quarter of 2023. Processed approximately 760,300 tests in the second quarter of 2024, compared to approximately 617,200 tests in the second quarter of 2023, an incr
8/8/24 4:05:00 PM ET
$NTRA
Medical Specialities
Health Care

$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,300 Today

Natera's Performance Over Last 5 Years

Chat with this insight

Recent Analyst Ratings for $NTRA

$NTRA Press Releases

Fastest customizable press release news feed in the world

Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM

Natera Reports Third Quarter 2024 Financial Results

Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer

$NTRA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies resumed coverage on Natera with a new price target

Craig Hallum resumed coverage on Natera with a new price target

Natera downgraded by Raymond James with a new price target

$NTRA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Marcus Gail Boxer sold $1,548,931 worth of shares (9,682 units at $159.98), decreasing direct ownership by 50% to 9,704 units (SEC Form 4)

Director Baynes Roy D. exercised 37,230 shares at a strike of $23.48 and sold $5,439,565 worth of shares (37,230 units at $146.11) (SEC Form 4)

CEO AND PRESIDENT Chapman Steven Leonard sold $677,574 worth of shares (4,628 units at $146.41) and sold $14,635 worth of Common Stok (100 units at $146.35), decreasing direct ownership by 2% to 185,034 units (SEC Form 4)

$NTRA Market Insights

Live Market Insights

$NTRA SEC Filings

(NTRA) - Analyzing Natera's Short Interest

Here's How Much You Would Have Made Owning Natera Stock In The Last 5 Years